Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00716807 · ClinicalTrials.gov registry record · NA
Efficacy of Nalbuphine and Naloxone Administered as Nose Sprays in the Treatment of Orofacial Pain
A NA study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- NA
- Development phase
- 46
- Enrollment target
NCT00716807 is a NA study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 46 participants.
The verdict
NCT00716807, a NA study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- NA
- Development phase
- 46 participants
- Enrollment target
Study Summary
Patients with chronic masticatory muscle pain (i.e., pain greater than three months) or patients with burning mouth syndrome participate in this study. The aim of the study is to compare the pain killing effectiveness of nalbuphine, a narcotic pain killer, administered with either placebo or naloxone, a drug used to treat opiate overdose. A second goal is to determine if there are sex differences in these two drug regimens. Drugs will be administered with single-use intranasal spray devices. All participants will receive two sprays (one spray per nostril). One of the two sprays will be nalbuphine (5 mg). The other spray will be naloxone in half the participants and placebo in the other half.
Interventions
- DRUG nalbuphine plus naloxone
- DRUG nalbuphine plus placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2008-01 |
| Est. Completion | 2010-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00716807
The ClinicalTrials.gov registry entry for NCT00716807 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which nalbuphine plus naloxone is the first listed.
NCT00716807 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00716807 about?
NCT00716807 is a clinical study titled "Efficacy of Nalbuphine and Naloxone Administered as Nose Sprays in the Treatment of Orofacial Pain". Patients with chronic masticatory muscle pain (i.e., pain greater than three months) or patients with burning mouth syndrome participate in this study. The aim of the study is to compare the pain killing effectiveness of nalbuphine, a narcotic pain killer, administered with either placebo or naloxon...
What is the current status of trial NCT00716807?
This trial is currently terminated. It is a NA study. The enrollment target is 46 participants. The study started on 2008-01. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00716807?
The interventions under investigation include: nalbuphine plus naloxone (DRUG), nalbuphine plus placebo (DRUG).
Who is sponsoring clinical trial NCT00716807?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.